{"filings":[{"id":1027838,"accession_number":"0002046386-26-000037","cik":2046386,"company_name":"Medline Inc.","ticker":"MDLN","form_type":"8-K","filed_at":"2026-06-12T20:20:00+00:00","items":["5.07"],"status":"ready","headline":"Medline shareholders elect 12 directors, approve executive compensation and auditor at 2026 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 12 director nominees elected; highest withheld votes were for Robert R. Schmidt with 43,976,750 withheld.","Advisory vote on executive compensation approved: 1,189,280,399 for, 6,203,145 against.","Advisory vote on frequency set to one year (1,195,424,539 votes); board adopts annual advisory vote.","Ratification of Ernst & Young as independent auditor for FY2026 approved: 1,211,242,117 for, 156,205 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":48107261289.333694,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":787958,"accession_number":"0001193125-26-252557","cik":2046386,"company_name":"Medline Inc.","ticker":"MDLN","form_type":"8-K","filed_at":"2026-06-02T12:06:32+00:00","items":["1.01","2.03","8.01","9.01"],"status":"ready","headline":"Medline issues $2.0B senior secured notes & refinances $2.75B term loan; secondary offering of 72.6M shares at $37","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Issued $1.25B of 5.000% senior secured notes due 2031 and $750M of 5.250% senior secured notes due 2033.","New $2.75B term loan facility (SOFR+1.50% or Base+0.50%) due 2033 refinances existing term loans.","Proceeds used to repay $724M of 2030 term loan and $500M of 6.250% notes due 2029.","Selling stockholders (Blackstone, Hellman & Friedman, ADIA) sold 72,554,594 shares at $37.00 per share.","Underwriters have a 30-day option to purchase up to an additional 10,883,189 shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48107261289.333694,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":97466,"accession_number":"0002046386-26-000022","cik":2046386,"company_name":"Medline Inc.","ticker":"MDLN","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medline Q1 sales up 10.7% to $7.4B; net income down 25.8%, adjusted EBITDA down 10.6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $239M (-25.8% YoY); Diluted EPS $0.16; Adjusted Diluted EPS $0.33.","Organic sales growth 10.1%; total sales $7.4B driven by new customer signings and existing customer growth.","Adjusted EBITDA $776M (-10.6% YoY) on higher tariffs, operating expenses, and IPO-related bonus.","Raising full-year organic sales guidance to 8.5%-9.5% (prior 8%-9%); maintaining adjusted EBITDA outlook $3.5-$3.6B.","Free Cash Flow $316M; net cash from ops $412M, capex for distribution centers and manufacturing."],"consensus_eps_estimate":null,"consensus_eps_actual":0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":7352000000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48107261289.333694,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112273,"accession_number":"0002046386-26-000007","cik":2046386,"company_name":"Medline Inc.","ticker":"MDLN","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Medline Q4 net income down 37.7% to $180M; FY25 EBITDA up 3.2%; guides FY26 organic sales growth 8-9%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net sales $7.8B (+14.8% YoY); net income $180M (-37.7%); Adj. EBITDA $805M (flat).","FY25 net sales $28.4B (+11.5%); net income $1.2B (-3.6%); Adj. EBITDA $3.5B (+3.2%).","FY25 organic sales growth 10.5%; net cash from ops $1.7B; Free Cash Flow $1.3B.","FY26 guidance: organic sales growth 8-9%; Adj. EBITDA $3.5-3.6B.","Margins pressured by tariffs and higher costs; $2.4B in new customer signings in 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":28432000000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":48107261289.333694,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":128856,"accession_number":"0001193125-25-328884","cik":2046386,"company_name":"Medline Inc.","ticker":"MDLN","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["1.01","3.03","5.03","5.02","8.01","9.01"],"status":"ready","headline":"Medline completes IPO of ~248M shares at $29; uses proceeds to repay debt and buy out pre-IPO owners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IPO closed Dec 18, 2025: 248,439,654 shares of Class A common stock at $29.00 per share.","Net proceeds from 179M shares ($5,078M) used to purchase Common Units; Medline Holdings repaid $731M under New Euro Term Loan and $3,292M under 2028 Refinancing Term Loan.","Proceeds from 37M shares ($1,051M) and 32.4M shares ($919M) from over-allotment used to purchase/redeem shares and Common Units from certain pre-IPO owners.","Todd M. Bluedorn appointed to Board and Audit Committee; granted RSUs with $300,000 grant date fair value vesting March 30, 2027.","Amended and restated certificate of incorporation and bylaws effective; authorized capital stock includes 50B shares Class A, 50B shares Class B, and 5B shares preferred."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":48107261289.333694,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}